Partners take a personalised approach to long Covid

Hospital patient on ventilator

GeNeuro and Verily will work together to investigate biomarkers related to activation of the proinflammatory HERV-W envelope protein (W-ENV) in SARS-CoV-2 infection.

Through this collaboration, the companies will build on results published earlier this year, which evidenced the in vitro activation of HERV-W by SARS-CoV-2 in susceptible individuals and the correlation between W-ENV protein levels in serum and lymphocytes with Covid-19 severity.

“Our research indicates that W-ENV contributes to Covid-19 disease severity and may explain manifestations of long Covid,” said Dr Hervé Perron, Chief Scientific Officer of GeNeuro. “This collaboration with Verily advances GeNeuro’s ambitions to treat patients with long Covid using a personalised medicine approach through biomarker identification of those more likely to present with severe disease.”

Verily will provide high-resolution multi-omic data generated from Covid-19 patient samples using its immune mapping platform, along with high-powered data analysis.

“We are excited to partner with GeNeuro to advance our shared belief that identification of actionable biomarkers early in disease can advance precision health and save lives,” said Charlie Kim, Head of Molecular Science at Verily. “This could be an important step toward earlier, more targeted interventions for patients with long Covid.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free